Key result
SLCO1B1 variants, hypothyroidism, and vitamin D deficiency are linked to increased risk of statin-associated muscle symptoms.
Why the study?
Does incorporating pharmacogenetic testing and addressing modifiable risk factors reduce adverse effects in patients receiving statin therapy?
Does incorporating pharmacogenetic testing and addressing modifiable risk factors reduce adverse effects in patients receiving statin therapy?
Answers are grounded in this paper and cite their sources.
Incorporating pharmacogenetic testing for SLCO1B1 and addressing modifiable risk factors like thyroid dysfunction and vitamin D deficiency may optimize statin therapy and reduce adverse effects.
Statins are first-line agents for managing dyslipidemia, primarily prescribed to reduce low-density lipoprotein cholesterol (LDL-C) and prevent atherosclerotic cardiovascular disease (ASCVD). Despite their proven efficacy, there is significant interindividual variability in statin response, with some patients experiencing adverse events such as statin-associated muscle symptoms (SAMS) and hepatotoxicity. These effects are partly attributable to genetic polymorphisms, particularly in the SLCO1B1 gene, which encodes the organic anion-transporting polypeptide 1B1 (OATP1B1) responsible for hepatic statin uptake. The SLCO1B1 rs4149056 polymorphism is associated with impaired transporter function, leading to elevated statin plasma concentrations and a higher risk of statin-induced myopathy, especially with simvastatin. Non-genetic factors, such as hypothyroidism, can exacerbate statin intolerance by impairing lipid metabolism and increasing the risk of myopathy and rhabdomyolysis due to reduced hepatic statin clearance. Vitamin D deficiency has also been linked to increased susceptibility to SAMS, as vitamin D plays a role in muscle function and statin metabolism through CYP enzyme modulation. Coenzyme Q10 (CoQ10) depletion, a consequence of statin therapy due to inhibition of the mevalonate pathway, may further contribute to mitochondrial dysfunction and muscle injury. Incorporating pharmacogenetic testing and addressing modifiable risk factors such as thyroid dysfunction and vitamin D deficiency may optimize statin therapy, reducing adverse effects while maintaining cardiovascular protection.
No takes yet. Share an insight, caveat, or question.
Marušić et al. (2026) conducted a review in Dyslipidemia and statin-associated side effects. SLCO1B1 polymorphism and non-genetic risk factors was evaluated. Genetic polymorphisms in the SLCO1B1 gene and non-genetic factors like hypothyroidism and vitamin D deficiency increase the risk of statin-associated muscle symptoms.
Synapse has enriched 10 related papers. Consider them for comparative context: